Oppenheimer lowers Moonlake Immunotherapeutics stock price target after mixed trial results
NegativeFinancial Markets

Oppenheimer has lowered its stock price target for Moonlake Immunotherapeutics following mixed results from recent clinical trials. This adjustment reflects concerns about the company's performance and the potential impact on investor confidence. As the biotech sector continues to navigate challenges, such updates are crucial for stakeholders to assess the viability of their investments.
— Curated by the World Pulse Now AI Editorial System